Una panorámica sobre patentes, vacunas y covid-19

Referencias bibliográficas

• Aars, O. K., Clark, M., & Schwalbe, N. (2021). Increasing efficiency in vaccine Production: A primer for change. Vaccine: X. 8. 100104. https://doi.org/10.1016/J.JVACX.2021.100104
• Agencia Española del Medicamento. (2020, 28 julio). Recomendaciones para el tratamiento con remdesivir de pacientes con COVID-19. Recuperado 27 de octubre de 2021, de https://www.aemps.gob.es/informa/notasinformativas/medicamentosusohumano-3/2020-medicamentosusohumano-3/recomendaciones-para-el-tratamiento-con-remdesivir-de-pacientes-con-covid-19/
• Asundi, A., O’Leary, C., & Bhadelia, N. (2021). Global COVID-19 vaccine inequity: The scope, the impact, and the challenges. Cell Host & Microbe. 29(7). 1036. https://doi.org/10.1016/J.CHOM.2021.06.007
• Biddle, J. (2014). “Can Patents Prohibit Research? On the Social Epistemology of Patenting and Licensing in Science.” Studies in History and Philosophy of Science 45. 14-23.
• Cebrián, M. y López, S. (2017). “Assessing the Impact of Field-of-Use Restrictions in Patent Licensing Agreements: The Ethical Pharmaceutical Industry in the United States”. 1950–1962. Enterprise & Society. 18(2). 282-323.
• Chandrasekharan, S., Amin, T., Kim, J., Furrer, E., Matterson, A. C., Schwalbe, N., & Nguyen, A. (2015). “Intellectual property rights and challenges for development of affordable human papillomavirus, rotavirus and pneumococcal vaccines: Patent landscaping and perspectives of developing country vaccine manufacturers”. Vaccine. 33(46). 6366–6370.
• Czochor, J., & Turchick, A. (2014). Introduction. The Yale Journal of Biology and Medicine. 87(4). 401. Retrieved from /pmc/articles/PMC4257027/
• Denicolò, V., & Franzoni, L. A. (2003). “The contract theory of patents”. International Review of Law and Economics. 23(4). 365–380. https://doi.org/10.1016/J.IRLE.2003.07.002
• Domínguez, N. (2021, 20 mayo). “Suspender las patentes no resolverá la escasez de vacunas”. El País. Recuperado de https://elpais.com
• Dong, Y., Dai, T., Wei, Y., Zhang, L., Zheng, M., & Zhou, F. (2020). “A systematic review of SARS-CoV-2 vaccine candidates”. Signal Transduction and Targeted Therapy. 5(1). https://doi.org/10.1038/S41392-020-00352-Y
• Dutfield, G. (2003). Intellectual Property Rights and the Life Science Industries A Twentieth Century History. Routledge. Abingdon, Reino Unido.
• Eccleston-Turner, M. (2017). “Beyond patents: Scientific knowledge, and access to vaccine”. Ethics, Medicine and Public Health. 3(1). 64–73. https://doi.org/10.1016/J.JEMEP.2017.02.011
• Eccleston-Turner, Mark, & Upton, H. (2021). “International Collaboration to Ensure Equitable Access to Vaccines for COVID‐19: The ACT‐Accelerator and the COVAX Facility”. The Milbank Quarterly. 99(2). 426. https://doi.org/10.1111/1468-0009.12503
• Forman, R., Shah, S., Jeurissen, P., Jit, M., & Mossialos, E. (2021). “COVID-19 vaccine challenges: What have we learned so far and what remains to be done?” Health Policy. 125(5). 553–567. https://doi.org/10.1016/J.HEALTHPOL.2021.03.013
• Gaviria, M., & Kilic, B. (2021). A network analysis of COVID-19 mRNA vaccine patents. Nature Biotechnology 2021 39. 5. 39(5). 546–548. https://doi.org/10.1038/s41587-021-00912-9
• Health Action International. (n.d.). C-TAP has not (yet) lived up to high expectations - Health Action International. Retrieved from https://haiweb.org/c-tap-has-not-yet-lived-up-to-high-expectations/
• Henry, B. (2018). “Drug pricing and challenges to hepatitis C treatment access”. Journal of health & biomedical law. 14(0). 265–283.
• Krishtel, P., & Hassan, F. (2021). “Share vaccine know-how”. Science. 374(6566). 379–379. https://doi.org/10.1126/SCIENCE.ABM8724
• Martínez, S. (2021, 10 junio). “La Eurocámara reclama liberar las patentes de las vacunas contra el covid”. El Periódico. Recuperado de https://www.elperiodico.com
• Mateos, A. (2021, 10 junio). “Sí del Parlamento Europeo a eliminar patentes en vacunas Covid”. Redacción Médica. Recuperado de https://www.redaccionmedica.com
• Matheson Am, S., & Kirkinis, A. (2021). “Compulsory licence and Crown use provisions in the Covid-19 pandemic—the Australian perspective”. Journal of Intellectual Property Law & Practice. 16(6). 484–497. https://doi.org/10.1093/JIPLP/JPAB070
• McAdams, D., McDade, K. K., Ogbuoji, O., Johnson, M., Dixit, S., & Yamey, G. (2020). “Incentivising wealthy nations to participate in the COVID-19 Vaccine Global Access Facility (COVAX): a game theory perspective”. BMJ Global Health. 5(11). https://doi.org/10.1136/BMJGH-2020-003627
• McMahon, A. (2020). “Global equitable access to vaccines, medicines and diagnostics for COVID-19: The role of patents as private governance”. Journal of Medical Ethics. 47(3). 142–148. https://doi.org/10.1136/MEDETHICS-2020-106795
• Moon, S., Alonso Ruiz, A., & Vieira, M. (2021). “Averting Future Vaccine Injustice. New England” Journal of Medicine. 385(3). 193–196. https://doi.org/10.1056/NEJMP2107528/SUPPL_FILE/NEJMP2107528_DISCLOSURES.PDF
• Médicos Sin Fronteras. (2021, 7 abril). Pedro Sánchez: no a las patentes, la pandemia no es un negocio. Recuperado 19 de octubre de 2021, de https://www.msf.es/firma-patente-vacuna-covid
• Nordhaus, W. D. (1969). “An Economic Theory of Technological Change”. The American Economic Review. 59(2). 18–28. http://www.jstor.org/stable/1823649
• Parthasarathy, S. (2017). Patent Politics Life Forms, Markets, and the Public Interest in the United States and Europe. University of Chicago Press. Chicago, EEUU.
• Peacocke, E. F., Heupink, L. F., Frønsdal, K., Dahl, E. H., & Chola, L. (2021). “Original research: Global access to COVID-19 vaccines: a scoping review of factors that may influence equitable access for low and middle-income countries”. BMJ Open. 11(9). https://doi.org/10.1136/BMJOPEN-2021-049505
• Perehudoff, K., Thoen, E., & Boulet, P. (2021). “Overriding drug and medical technology patents for pandemic recovery: a legitimate move for high-income countries, too”. BMJ Global Health. 6(4). e005518. https://doi.org/10.1136/BMJGH-2021-005518
• Sánchez, V. (2021, 3 junio). “Covid-19: ¿por qué hay oposición al levantamiento de patentes de las vacunas?” France24. Recuperado de https://www.france24.com
• The Guardian. (n.d.). “WHO platform for pharmaceutical firms unused since pandemic began | World Health Organization” The Guardian. Retrieved from https://www.theguardian.com/world/2021/jan/22/who-platform-for-pharmaceutical-firms-unused-since-pandemic-began
• The Pharma Letter. (2021, 1 junio). Russian government finally approves compulsory licensing of original drugs. Recuperado 2 de noviembre de 2021, de https://www.thepharmaletter.com/article/russian-government-finally-approves-compulsory-licensing-of-original-drugs
• Uddin, M., Mustafa, F., Rizvi, T. A., Loney, T., Al Suwaidi, H., Al-Marzouqi, A. H. H., … Senok, A. C. (2020). “SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology. Vaccines, and Therapeutic Interventions”. Viruses. 12(5). https://doi.org/10.3390/V12050526
• Usher, A. D. (2020). “South Africa and India push for COVID-19 patents ban”. The Lancet. 396(10265). 1790–1791. https://doi.org/10.1016/S0140-6736(20)32581-2
• van de Pas, R., Widdowson, M.-A., Ravinetto, R., N Srinivas, P., Ochoa, T. J., Fofana, T. O., & Van Damme, W. (2021). “COVID-19 vaccine equity: a health systems and policy perspective”. Expert Review of Vaccines. https://doi.org/10.1080/14760584.2022.2004125
• van Riel, D., & de Wit, E. (2020). “Next-generation vaccine platforms for COVID-19”. Nature Materials 2020 19:8. 19(8). 810–812. https://doi.org/10.1038/s41563-020-0746-0
• Wang, J., Peng, Y., Xu, H., Cui, Z., & Williams, R. O. (2020). “The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation”. AAPS PharmSciTech. 21(6). https://doi.org/10.1208/S12249-020-01744-7
• Warren, E. (2021, 12 de octubre). Carta a WH y BARDA sobre el Contrato de Moderna https://www.warren.senate.gov/imo/media/doc/2021.10.12%20Letter%20to%20WH%20and%20BARDA%20on%20Moderna%20Contract.pdf
• WHO. (n.d.-a). C-TAP: A concept paper. Retrieved November 15, 2021, from https://www.who.int/publications/m/item/c-tap-a-concept-paper
• WHO. (n.d.-b). COVID-19 technology access pool. Retrieved November 15, 2021, from https://www.who.int/initiatives/covid-19-technology-access-pool
• WHO. (n.d.-c). “Costs of Delivering COVID-19 Vaccine in 92 AMC Countries: Updated Estimates from COVAX Working Group on Delivery Costs.” Retrieved November 15. 2021 from https://www.who.int/docs/default-source/coronaviruse/act-accelerator/covax/costs-of-covid-19-vaccine-delivery-in-92amc_08.02.21.pdf
• WIPO. (2012). Patent Landscape Report on Vaccines for Selected Infectious Diseases. Recuperado de https://www.wipo.int/edocs/pubdocs/en/patents/946/wipo_pub_946_3.pdf
• WTO. (n.d.). WTO | intellectual property (TRIPS) - agreement text - standards. Retrieved November 15, 2021, from https://www.wto.org/english/docs_e/legal_e/27-trips_04c_e.htmgestión